ArticleHepatology international2012
Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network.
Article in Hepatology international, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC medicine · 2024Pooled it
- Prevalence and Significance of Antinuclear Antibodies in Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.Disease markers · 2022Pooled it
- Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.World journal of gastroenterology · 2018Pooled it
- Natural Autoantibodies Negatively Correlate with Hepatocellular Carcinoma Incidence in Cirrhosis.Cancer research communications · 2026Article
- Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease.Arthritis care & research · 2026Article
- Not always autoimmune hepatitis: Hepatic steatosis is associated with autoantibodies positivity in patients with hepatocellular dysfunction.World journal of hepatology · 2026Article
- Autoantibodies are associated with worse outcomes in MASLD.JHEP reports : innovation in hepatology · 2025Article
- Autoimmune mechanisms and inflammation in obesity-associated type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease.Functional & integrative genomics · 2025Review
- Role of autoimmune phenomena in nonalcoholic fatty liver disease: Insights and limitations.World journal of hepatology · 2025Article
- Association of antinuclear antibody positivity with liver disease severity in pediatric metabolic dysfunction-associated steatotic liver disease.Frontiers in pediatrics · 2025Article
- Evaluation of autoimmune phenomena in patients with nonalcoholic fatty liver disease on the basis of liver pathology.World journal of hepatology · 2024Article
- Exploring autoantibodies as predictors of severe fibrosis or cirrhosis in metabolic dysfunction associated with steatotic liver disease.Canadian liver journal · 2024Article
- Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.Journal of hepatology · 2023Review
- Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease.JHEP reports : innovation in hepatology · 2023Article
- Prevalence and Significance of Autoantibody Seropositivity in Children with Wilson's Disease.Diagnostics (Basel, Switzerland) · 2023Article
- Non-alcoholic fatty liver disease: the pathologist's perspective.Clinical and molecular hepatology · 2023Review
- Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD).EXCLI journal · 2023Review
- Presence of Serum Antinuclear Antibodies Does Not Impact Outcomes in HBV-Related Acute-on-Chronic Liver Failure.Canadian journal of gastroenterology & hepatology · 2022Article
- Immunoglobulin G in non-alcoholic steatohepatitis predicts clinical outcome: A prospective multi-centre cohort study.World journal of gastroenterology · 2021Article
- Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common.Metabolism and target organ damage · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
purposeSome studies have suggested that autoantibodies might define a subcategory and phenotype of nonalcoholic fatty liver disease (NAFLD) associated with advanced histological features. We evaluated the relationship between the presence of serum autoantibodies and liver histology in a large cohort of well-characterized patients with NAFLD.
methodsA total of 864 NAFLD patients participating in two prospective multicentre clinical studies underwent testing for serum autoantibodies within 24 months of a liver biopsy. Liver histology was compared between the patients with and without ANA ≥ 1:160 or ASMA ≥ 1:40 or both.
resultsAutoantibodies were present in 182 patients (21%). There was no difference in age, gender, race, body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR), or history of diabetes between the two groups. Biopsies in subjects with autoantibodies were less likely to have moderate-to-severe steatosis (i.e., >33%) compared to controls (57.1 vs. 43.0%, P value = 0.0006). Lobular inflammation (46.7 vs. 47.5%), ballooning degeneration (38.5 vs. 42.5%), and advanced fibrosis (33.2 vs. 29.3%) were not different between the two groups. Histologic evidence of 'definite' NASH did not differ significantly between the two groups (55.5 vs. 58.9%). After adjusting for age, gender, BMI, race, and diabetes, the presence of autoantibodies was independently associated with lower prevalence of moderate-to-severe steatosis [odds ratio (OR), 0.58; 95% confidence interval (CI), 0.41-0.82; P = 0.01].
conclusionAutoantibodies are frequently positive in NAFLD in the absence of autoimmune hepatitis and their occurrence is not associated with more advanced histologic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.